Portugal news in English.

Subscribe

Latest

Pharma

Hovione Names António Almeida and Marco Gil Co-CEOs as Jean-Luc Herbeaux Steps Down on 21 May After Three-Year Run — Both Incoming Executives Carry 19-Year Tenures and the Permanent CEO Search Is Already Open

Hovione, Portugal's flagship pharmaceutical contract-development-and-manufacturing group, will replace Jean-Luc Herbeaux with a two-person co-CEO bridge on 21 May 2026. António Almeida (CFO) and Marco Gil (SVP Sales & Marketing) take the top job jointly; both joined Hovione in 2007.

Government

Tribunal de Contas Detects 49 Oeiras Directors Operating 'Without Legal Legitimacy' — Auditoria de Apuramento de Responsabilidades Financeiras Walks Into the Ministério Público, Seixal Adds Six Years of Direção em Substituição Across Two Mandates

TdC's Auditorias de Apuramento de Responsabilidades Financeiras land at the Ministério Público: 49 Oeiras directors held posts past the 90-day substituição cap, Seixal ran its leadership em substituição for six-plus years, and the financial-responsibility door is now open.

Infrastructure

Cascais's 'Free Lunch' Walks Into Porto and Viseu — Pedro Duarte Locks a €20.5 Million Free-Transit Contract for 1 July, Viseu Approves a €1 Million Universal Pass on 8 May and the Tribunal de Contas Becomes the Last Gate

Porto signs a €20.5M/year free-transit contract for residents across the entire AMP, targeting 1 July activation pending Tribunal de Contas visto. Viseu adds a €1M universal pass on 8 May. The Cascais Viver model is going national, one Câmara at a time.

Environment

Despacho 5797/2026 Walks the APA and ICNF Restructuring Into a 28 June Diagnostic Deadline — Gonçalo Matias and Graça Carvalho Promise AI-Driven Licensing and a Pivot From Prior Control to Post-Facto Inspection

Despacho 5797/2026 opens the inter-ministerial restructuring of APA and ICNF with a 28 June diagnostic deadline. Matias and Graça Carvalho commit to AI-driven licensing and a pivot from prior control to post-facto inspection. Zero, Quercus, WWF and SPEA push back.